Gallo R C, Perry S
J Clin Invest. 1969 Jan;48(1):105-16. doi: 10.1172/JCI105958.
(1) Synthesis of deoxythymidine by either direct transfer of deoxyribosyl to thymine (pyrimidine deoxyribosyltransferase) or by a coupled deoxynucleoside phosphorylase mechanism is approximately twofold greater with normal leukocyte extracts (55 to 88% granulocytes) than with extracts prepared from leukocytes obtained from patients with chronic myelogenous leukemia. Activities in lymphocytes (normal or leukemic) are one-fifth the activity of normal granulocytes.(2) The lower activity in chronic myelogenous leukemia remains at 50% of normal even when patients are in hematologic remission with a normal per cent mature granulocytes in the peripheral blood.(3) The leukemic enzyme could not be distinguished from the normal by pH optima, thermal stability, or kinetic properties. The Km's for the deoxyribosyl acceptor and deoxyribosyl donors were identical for both enzymes. Both are subject to substrate inhibition by thymine and to inhibition by purine bases with similar Ki's. In addition, the transferase component of both the leukemic and the normal cell enzyme is activated by phosphate and arsenate. It appears, therefore, that there is no qualitative difference between the enzyme obtained from leukocytes of patients with chronic myelogenous leukemia and the enzyme obtained from normal leukocytes, suggesting that the difference in total cell activity is due to an actual decrease in amount of enzyme in chronic myelogenous leukemia or to a mixed cell population, one with a normal quantity of enzyme and the other with little or no active enzyme.(4) In both the normal cell and the leukemic cell extracts, transferase and phosphorylase activities could not be separated. The ratio of the two activities remained constant over a 140- and a 230-fold purification in normal and leukemic cell extracts, respectively. These and other observations indicate that transferase and phosphorylase activities are associated with the same protein.(5) The metabolism of pyrimidine and purine deoxynucleosides is similar for normal and leukemic cells. Catabolism of all deoxynucleosides tested was by direct phosphorolysis, except for deoxyadenosine which required initial deamination to deoxyinosine before phosphorolysis. In contrast to the greater rates of pyrimidine deoxynucleoside synthesis and cleavage with normal leukocyte extracts, the rates of purine deoxynucleoside synthesis and cleavage were approximately twofold greater with extracts prepared from cells of patients with chronic myelogenous leukemia. There was no significant difference in the rate of phosphorolytic cleavage of pyrimidine nucleosides (uridine) between the CML and normal leukocyte extracts.
(1) 正常白细胞提取物(55%至88%为粒细胞)通过将脱氧核糖基直接转移至胸腺嘧啶(嘧啶脱氧核糖基转移酶)或通过偶联的脱氧核苷磷酸化酶机制合成脱氧胸苷的能力,比慢性粒细胞白血病患者白细胞提取物的相应能力大约高两倍。淋巴细胞(正常或白血病细胞)中的活性仅为正常粒细胞活性的五分之一。(2) 即使慢性粒细胞白血病患者处于血液学缓解状态且外周血中成熟粒细胞百分比正常,其较低的活性仍维持在正常水平的50%。(3) 白血病酶与正常酶在最适pH、热稳定性或动力学特性方面无法区分。两种酶对脱氧核糖基受体和脱氧核糖基供体的Km值相同。两者均受胸腺嘧啶的底物抑制以及嘌呤碱的抑制,且抑制常数相似。此外,白血病细胞和正常细胞酶的转移酶成分均被磷酸盐和砷酸盐激活。因此,似乎慢性粒细胞白血病患者白细胞中获得的酶与正常白细胞中获得的酶在性质上没有差异,这表明总细胞活性的差异是由于慢性粒细胞白血病中酶的实际量减少,或者是由于混合细胞群体,其中一个群体酶量正常,另一个群体几乎没有或没有活性酶。(4) 在正常细胞和白血病细胞提取物中,转移酶和磷酸化酶活性均无法分离。在正常细胞提取物和白血病细胞提取物中,分别经过140倍和230倍纯化后,这两种活性的比例保持恒定。这些及其他观察结果表明,转移酶和磷酸化酶活性与同一种蛋白质相关。(5) 正常细胞和白血病细胞中嘧啶和嘌呤脱氧核苷的代谢相似。除脱氧腺苷需先脱氨生成脱氧肌苷再进行磷酸解外,所有测试的脱氧核苷的分解代谢均通过直接磷酸解进行。与正常白细胞提取物中嘧啶脱氧核苷合成和裂解速率更高相反,慢性粒细胞白血病患者细胞提取物中嘌呤脱氧核苷合成和裂解速率大约高两倍。慢性粒细胞白血病患者和正常白细胞提取物中嘧啶核苷(尿苷)的磷酸解裂解速率没有显著差异。